Oral News and Research

RSS

Treating gum disease could help people with Type 2 diabetes manage their blood glucose levels

A study funded by Diabetes UK has found that treating periodontitis (gum disease) could help people with Type 2 diabetes manage their blood glucose levels, and may reduce their risk of diabetes-related complications.

25 Oct 2018

FDA approves new antiviral flu treatment

Today, the U.S. Food and Drug Administration approved Xofluza (baloxavir marboxil) for the treatment of acute uncomplicated influenza (flu) in patients 12 years of age and older who have been symptomatic for no more than 48 hours.

24 Oct 2018

Novel drug extends survival for women with HR-positive metastatic breast cancer

The drug palbociclib, used in combination with standard treatment, improved survival for women with hormone receptor-positive metastatic breast cancer, according to a large phase III clinical trial.

24 Oct 2018

Biomarkers can predict treatment response in women with endometriosis

Biomarkers can predict whether women will respond to the first-line treatment for endometriosis, an extremely painful condition in which the tissue usually found inside the uterus grows in places it shouldn't, according to a new study published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism.

24 Oct 2018

New liquid biopsy test confirms remission in patients with HPV-associated oropharyngeal cancer

A highly sensitive blood test that detects minute traces of cancer-specific DNA has been shown to accurately determine whether patients with HPV-related oropharyngeal squamous cell carcinoma are free from cancer following radiation therapy.

23 Oct 2018

AbbVie’s U-ACHIEVE Phase 2b/3 dose-ranging study improves outcomes in patients with ulcerative colitis

AbbVie, a research-based global biopharmaceutical company, today announced positive results from U-ACHIEVE, an ongoing Phase 2b/3 dose-ranging study evaluating upadacitinib, an investigational JAK1-selective inhibitor, for induction and maintenance therapy in adult patients with moderately to severely active ulcerative colitis.

23 Oct 2018

Study: Targeting specific genomic mutation in breast cancer improves survival

Targeting a common mutation in patients with hormone receptor positive (HR+) HER2 negative (HER2-) advanced breast cancer with the alpha-specific phosphatidylinositol-3-kinase (PI3K) inhibitor alpelisib significantly improves progression-free survival, according to late-breaking results reported at ESMO 2018.

22 Oct 2018

People with periodontal disease less likely to reach healthy blood pressure ranges

People with high blood pressure taking medication for their condition are more likely to benefit from the therapy if they have good oral health, according to new research in the American Heart Association's journal Hypertension.

22 Oct 2018

FOTIVDA expected to be included in new ESMO guidelines for advanced renal cell carcinoma

EUSA Pharma welcomes the news that FOTIVDA (tivozanib) is expected to be included in the upcoming European Society of Medical Oncology clinical practice guidelines for advanced renal cell carcinoma, anticipated to be published at the end of this year.

22 Oct 2018

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Bristol-Myers Squibb Company today announced four-year data from the Phase 3 CheckMate -067 clinical trial - the longest follow-up to date - which continues to demonstrate durable, long-term survival benefits with the first-line combination of Opdivo (nivolumab) and Yervoy (ipilimumab), versus Yervoy alone, in patients with advanced melanoma.

22 Oct 2018

$Phase III LONSURF study shows progression-free survival in patients with refractory metastatic gastric cancer$

Phase III LONSURF study shows progression-free survival in patients with refractory metastatic gastric cancer

Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), jointly announced today clinical data from the pivotal Phase III TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine/tipiracil, TAS-102) versus placebo and best supportive care in patients with heavily pre-treated metastatic gastric cancer who have progressed or are intolerant to previous lines of therapy.

22 Oct 2018

Pfizer announces PALOMA-3 trial results in patients with HR+, HER2- metastatic breast cancer

Pfizer Inc. today announced detailed overall survival data from the PALOMA-3 trial, which evaluated IBRANCE (palbociclib) in combination with fulvestrant compared to placebo plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer whose disease progressed on or after prior endocrine therapy.

22 Oct 2018

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck, known as MSD outside the United States and Canada, today announced the first presentation of results from an interim analysis of KEYNOTE-057, a Phase 2 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, for previously treated patients with high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ or CIS plus papillary disease (Cohort A).

22 Oct 2018

11th World Stroke Congress examines high stroke impact in low- and middle-income countries

11th World Stroke Congress brings together leading international stroke experts and an unparalleled scientific program covering epidemiology, prevention, acute care, recovery and rehabilitation in 100s of sessions and oral posters.

22 Oct 2018

X4 Pharmaceuticals announces clinical data of X4P-001-IO and Opdivo in patients with clear cell renal cell carcinoma

X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 antagonists to improve immune cell trafficking to treat cancer and rare disease, today announced results from a pilot study of X4P-001-IO in combination with Opdivo (nivolumab) in patients with clear cell renal cell carcinoma who are non-responsive to the anti-PD-1 checkpoint inhibitor Opdivo alone.

22 Oct 2018

Incidence of stroke has risen steadily among marijuana users, show studies

11th World Stroke Congress brings together leading international stroke experts and an unparalleled scientific program covering epidemiology, prevention, acute care, rehabilitation and recovery in 100s of sessions and oral posters.

19 Oct 2018

LJI and UC San Diego awarded $ 4.5 million as part of NCI's Cancer Moonshot initiative

Researchers at La Jolla Institute for Immunology and UC San Diego have been awarded $ 4.5 million as part of the National Cancer Institute's Cancer Moonshot initiative.

19 Oct 2018

Key insights into the application, production of bioactive materials

Anatomy, Modeling and Biomaterial Fabrication for Dental and Maxillofacial Applications provides readers with information about dental implants and biomaterial fabrication for maxillofacial procedures and dental bone / tissue repair.

19 Oct 2018

New pragmatic study launched to understand the effectiveness of new type 2 diabetes drug

HealthCore, Inc., the outcomes research subsidiary of Anthem, Inc. and Novo Nordisk Inc., which manufacturers the once weekly GLP-1 receptor agonist Ozempic (semaglutide), are working together to launch the first of its kind pragmatic study to understand the benefits of semaglutide as compared with all other available diabetes drugs in a real-world pragmatic clinical trial for Type 2 diabetes - one of the nation's fastest growing chronic diseases.

17 Oct 2018

Using Galleria mellonella to assess acute toxicity of chemicals

TruLarv is considered a non-animal technology in the context of UK animal use regulations where procedures on this species are not regulated.

17 Oct 2018

Oral News and Research

Treating gum disease could help people with Type 2 diabetes manage their blood glucose levels

FDA approves new antiviral flu treatment

Novel drug extends survival for women with HR-positive metastatic breast cancer

Biomarkers can predict treatment response in women with endometriosis

New liquid biopsy test confirms remission in patients with HPV-associated oropharyngeal cancer

AbbVie’s U-ACHIEVE Phase 2b/3 dose-ranging study improves outcomes in patients with ulcerative colitis

Study: Targeting specific genomic mutation in breast cancer improves survival

People with periodontal disease less likely to reach healthy blood pressure ranges

FOTIVDA expected to be included in new ESMO guidelines for advanced renal cell carcinoma

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Phase III LONSURF study shows progression-free survival in patients with refractory metastatic gastric cancer

Pfizer announces PALOMA-3 trial results in patients with HR+, HER2- metastatic breast cancer

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

11th World Stroke Congress examines high stroke impact in low- and middle-income countries

X4 Pharmaceuticals announces clinical data of X4P-001-IO and Opdivo in patients with clear cell renal cell carcinoma

Incidence of stroke has risen steadily among marijuana users, show studies

LJI and UC San Diego awarded $ 4.5 million as part of NCI's Cancer Moonshot initiative

Key insights into the application, production of bioactive materials

New pragmatic study launched to understand the effectiveness of new type 2 diabetes drug

Using Galleria mellonella to assess acute toxicity of chemicals

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News